ACR Hybrid Analysis of Certolizumab Pegol Plus Methotrexate in Patients With Active Rheumatoid Arthritis: Data From the RAPID 1 Trial

Por van Vollenhoven, R.F., Felson, D., Strand, V., Weinblatt, M.E., Luijtens, K., Keystone, E. C.
Publicado em 2011

Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis

Por Furst, D E, Shaikh, S A, Greenwald, M, Bennett, B, Davies, O, Luijtens, K, Staelens, F, Koetse, W, Bertin, P
Publicado no Arthritis Care Res (Hoboken) (2015)

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

Por Smolen, J, Landewé, R B, Mease, P, Brzezicki, J, Mason, D, Luijtens, K, van Vollenhoven, R F, Kavanaugh, A, Schiff, M, Burmester, G R, Strand, V, Vencovský, J, van der Heijde, D
Publicado em 2008